Thyrocare Technologies Limited share price

Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates through three segments: Diagnostic Testing Services, Imaging Services, and Others. The Diagnostic Testing Services segment engages in the selling of consumables used for collection, and promotion of pathology. The Imaging Services segment sells radio-pharmaceutical and consumables for reporting. The Others segment engages in the sale of glucometer and glucostrips under the brand name sugarscan. The company offers diagnostic and pathological services. The company was founded in 1996 and is based in Navi Mumbai, India. Thyrocare Technologies Limited is a subsidiar…Read more

Website NSE हिंदी में BSE

HealthcareDiagnostics & ResearchNifty Microcap 250NSE: THYROCAREISIN INE594H01019

16 Oct 2026, 3:30 PM IST₹485.25▼ 2.30 (0.47%)

Market Cap₹ 7,723 Cr.
Current Price₹ 485.25
High / Low₹ 662 / 343
Stock P/E44.0
Book Value₹ 37
Dividend Yield1.91 %
ROCE33.8 %
ROE28.80 %
Face Value₹ 10.0

More figures (10)

EPS (TTM)₹ 11.02
Price / Book13.19
OPM24.9 %
Debt / Equity0.09
Sales growth (5Y)10.9 %
Profit growth (5Y)7.6 %
Promoter holding51.2 %
EV / EBITDA29.0
Beta0.45
All-time high₹ 1,090

Price chart

Price on NSE 50 DMA 200 DMA Volume

Returns	1M	3M	6M	YTD	1Y	3Y CAGR	5Y CAGR
THYROCARE	-10.35%	-7.97%	+23.05%	+8.87%	+14.11%	+36.64%	+4.60%
Nifty 50	-0.31%	-3.85%	-4.34%	-11.42%	-9.53%	+5.46%	+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

Thyrocare Technologies Limited is in the Diagnostics & Research industry (Healthcare), with a market value of ₹7,723 crore.
It trades at 44.0 times its last 12 months' earnings and 13.2 times book value.
Revenue grew 10.9% a year over the last 5 years, profit 7.6% a year.
Return on equity was 28.8% and return on capital employed 33.8% in the latest year.
Debt was 0.09 times shareholders' equity.
The share price is 26.7% below its 52-week high and up 14.1% over one year.
Promoters and insiders hold about 51.2%; institutions about 22.0%.

Pros

Strong return on equity: 19.7% on average over the last 3 years.
Company is almost debt-free (debt is 0.09 times equity).
Latest quarter (Jun 2026): sales up 24% and profit up 34% from a year ago.
Trades at 44.0 times earnings, below its 3-year median of 53.0.
Pays a healthy dividend: about 91% of profit last year.

Cons

Promoter holding has fallen by 20.09 points over 3 years, to 51.02%.
Trades at 13.2 times its book value.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About Thyrocare Technologies Limited

Employees: 1,906
Head office: Navi Mumbai
NSE industry: Healthcare

HealthcareHealthcareDiagnostics & Research

Part ofNifty Microcap 250

S.No.	Company	CMP ₹	P/E	Mar Cap ₹ Cr	Div Yld %	NP Qtr ₹ Cr	Qtr Profit Var %	Sales Qtr ₹ Cr	Qtr Sales Var %	ROCE %	ROE %	P/B	OPM %	Debt / Eq	Prom. Hold. %	Sales ₹ Cr	Sales Var 3Yrs %
1.	Thyrocare Technologies	485.25	44.0	7,723	1.91	51	34.06	240	24.34	33.8	28.8	13.19	24.9	0.09	51.18	829	10.9
2.	Sun Pharmaceutical Industries	1,758.80	34.9	4,21,995	0.91	2,895	34.65	15,184	18.48	17.9	14.7	5.05	23.4	0.06	55.61	58,220	10.4
3.	Divi's Laboratories	9,144.50	83.0	2,42,758	0.33	902	36.25	3,080	19.15	19.0	16.2	14.48	28.4	0.00	52.00	10,476	11.0
4.	Torrent Pharmaceuticals	4,558.90	72.8	1,73,406	0.83	566	3.28	4,835	54.57	9.1	27.1	18.39	25.0	1.79	63.18	13,753	13.3
5.	Apollo Hospitals Enterprise	7,890.00	54.3	1,13,446	0.25	581	49.05	7,044	25.95	19.2	21.9	11.97	11.7	0.90	28.39	24,911	14.8
6.	Zydus Lifesciences	1,123.00	25.0	1,12,020	0.09	940	-19.74	7,802	24.03	19.0	19.7	4.17	21.7	0.46	75.18	26,720	16.5
7.	Cipla	1,325.10	31.8	1,07,051	0.98	789	-35.42	7,077	7.26	14.9	11.8	3.11	17.5	0.02	31.13	27,712	7.2
8.	Dr. Reddy's Laboratories	1,233.00	31.0	1,02,707	0.66	444	-68.72	8,071	-5.56	14.2	12.1	2.68	14.9	0.21	30.14	33,593	11.0
9.	Max Healthcare Institute	846.00	56.7	82,342	0.23	323	4.87	2,366	16.70	12.6	14.3	7.66	22.8	0.32	28.20	8,225	22.4
10.	Abbott India	26,170.00	34.4	55,609	2.01	429	17.13	1,814	4.33	41.9	34.5	11.65	26.3	0.04	75.54	6,927	9.0
	Median: 12 Co.	1,541.95	49.2	1,04,879	0.75	573	11.00	5,939	18.81	18.5	19.7	11.81	24.2	0.15	51.59	19,332	11.1

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Quarterly Results

Consolidated figures in ₹ crore /

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	135	148	135	154	157	177	166	187	193	217	196	224	240
YOY Sales Growth %	5.56%	9.65%	5.24%	13.52%	16.32%	19.84%	23.14%	21.34%	23.02%	22.09%	17.85%	19.66%	24.34%
	100	110	103	120	114	129	124	129	135	145	138	149	163
Material Cost %	28%	29%	29%	30%	29%	29%	27%	26%	29%	28%	24%	25%	26%
Employee Cost %	21%	18%	20%	17%	18%	17%	21%	18%	17%	15%	18%	16%	17%
Other Expenses %	26%	27%	28%	31%	26%	27%	26%	25%	24%	24%	28%	25%	25%
Operating Profit	35	38	32	34	43	48	42	58	58	71	58	75	77
OPM %	26%	25%	23%	22%	27%	27%	25%	31%	30%	33%	30%	34%	32%
	1	2	3	3	4	3	4	5	5	3	5	4	4
Exceptional items				-0							-6
Interest	1	1	1	1	1	1	1	1	1	1	-0	2	1
Depreciation	10	11	13	13	11	13	17	14	11	12	22	14	12
Profit before tax	25	28	20	23	34	37	28	48	50	62	35	64	68
	31%	28%	26%	25%	28%	-28%	32%	54%	24%	24%	21%	25%	25%
Current tax	9	9	5	7	10	-12	11	14	14	17	10	16	18
Deferred tax	-1	-1	-0	-1	-0	2	-2	11	-2	-2	-3	-0	-2
	17	20	15	17	24	47	19	22	38	48	28	49	51
Profit from associates	0	0	0		-0	-0	-0	-1	0	0	0	1	1
Minority share		-0	-1	-1	-0	-0	-0	-0	-1	-0	-1	2	-1
Profit to shareholders		20	15	18	24	27	19	22	39	48	29	47	52
YOY Profit Growth %	-20.62%	31.76%	0.27%	37.55%	38.78%	131.81%	28.56%	25.55%	59.94%	1.45%	48.02%	125.78%	34.06%
EPS in Rs	1.09	1.28	0.93	1.18	1.51	1.66	1.19	1.39	2.45	3.02	1.82	2.99	3.23
Raw filing

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	124	136	123	141	144	163	153	174	179	202	182	211	226
YOY Sales Growth %	3.66%	8.83%	4.88%	13.15%	16.20%	19.63%	24.14%	23.11%	24.55%	24.03%	19.62%	21.17%	26.14%
	90	100	92	108	101	114	112	118	122	133	124	138	150
Material Cost %	29%	30%	30%	31%	30%	29%	28%	27%	29%	28%	25%	26%	26%
Employee Cost %	22%	19%	20%	18%	18%	17%	22%	18%	17%	16%	18%	16%	16%
Other Expenses %	22%	24%	25%	27%	22%	24%	24%	23%	22%	22%	26%	24%	24%
Operating Profit	33	37	31	34	42	49	40	56	57	69	58	73	76
OPM %	27%	27%	25%	24%	29%	30%	26%	32%	32%	34%	32%	34%	34%
	0	2	2	3	3	2	4	5	4	2	3	4	4
Exceptional items											-6
Interest	1	1	1	1	1	1	0	1	1	1	-0	1	1
Depreciation	9	9	11	10	9	10	15	12	9	10	20	13	11
Profit before tax	24	28	21	25	35	40	28	48	51	61	37	62	67
	31%	28%	28%	23%	28%	27%	32%	54%	29%	29%	29%	30%	25%
Current tax	9	9	5	7	10	12	11	14	14	17	10	16	18
Deferred tax	-1	-1	0	-1	-0	-2	-2	11	1	1	1	2	-2
	17	20	15	19	25	30	19	22	36	43	26	44	50
YOY Profit Growth %	-16.85%	41.89%	17.89%	93.66%	50.33%	45.81%	28.27%	14.14%	43.34%	45.45%	36.91%	98.54%	39.17%
EPS in Rs	1.05	1.28	0.94	1.21	1.58	1.86	1.18	1.36	2.27	2.71	1.64	2.75	3.15
Raw filing

Source: the company's results filed with NSE, as reported. EPS restated for bonus issues and splits. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Consolidated figures in ₹ crore /

₹ Cr	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	403	433	495	589	527	572	687	829	876
YOY Sales Growth %		7.52%	14.18%	19.05%	-10.56%	8.58%	20.19%	20.61%
	249	261	323	354	407	434	497	567	594
Material Cost %	27%	27%	33%	29%	31%	29%	28%	26%	26%
Employee Cost %	11%	11%	12%	10%	20%	19%	18%	17%	17%
Other Expenses %	24%	22%	21%	21%	26%	28%	26%	25%	26%
Operating Profit	154	173	171	235	120	137	190	262	282
OPM %	38%	40%	35%	40%	23%	24%	28%	32%	32%
	10	8	12	29	8	9	15	17	16
Exceptional items		-7						-6	-6
Interest	1	2	1	2	2	4	3	3	3
Depreciation	26	32	30	34	39	47	55	59	60
Profit before tax	137	140	153	228	87	96	147	211	229
	39%	37%	26%	23%	28%	28%	37%	24%	24%
Current tax	53	43	44	56	30	30	48	57
Deferred tax	0	9	-5	-5	-6	-4	7	-7
	85	88	113	176	64	69	91	163	176
Profit from associates	1	1	-0	-0	1	0	-1	1	2
Minority share					-0	-1	-1	-0	-0
Profit to shareholders					64	71	92	163	176
YOY Profit Growth %		3.84%	27.97%	55.68%	-63.46%	7.97%	30.59%	79.45%
EPS in Rs	5.32	5.58	7.14	11.10	4.05	4.47	5.71	10.27	11.06
Dividend Payout %					123%	135%	104%	91%

Compounded Sales Growth

5 Years:: 11%
3 Years:: 16%
TTM:: 21%

Compounded Profit Growth

5 Years:: 8%
3 Years:: 36%
TTM:: 40%

Stock Price CAGR

5 Years:: 5%
3 Years:: 37%
1 Year:: 14%

Return on Equity

4 Years:: 18%
Last Year:: 29%

₹ Cr	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	370	400	474	562	486	524	633	774	821
YOY Sales Growth %		8.03%	18.57%	18.40%	-13.37%	7.72%	20.82%	22.30%
	222	233	304	331	374	390	446	518	546
Material Cost %	28%	28%	34%	29%	32%	30%	28%	27%	26%
Employee Cost %	11%	11%	12%	10%	21%	20%	19%	17%	16%
Other Expenses %	21%	19%	18%	19%	24%	25%	23%	23%	24%
Operating Profit	148	167	171	231	112	134	187	256	275
OPM %	40%	42%	36%	41%	23%	26%	30%	33%	34%
	14	10	12	7	5	7	13	13	13
Exceptional items		-44						-6	-6
Interest	0	1	1	2	2	4	3	2	3
Depreciation	14	20	21	28	34	39	47	51	53
Profit before tax	147	112	161	207	81	98	151	210	226
	35%	29%	26%	27%	30%	28%	37%	29%	28%
Current tax	53	43	44	56	30	30	48	57
Deferred tax	-1	-10	-3	-1	-6	-3	8	4
	95	79	120	152	57	71	96	149	163
YOY Profit Growth %		-16.71%	51.00%	26.95%	-62.53%	24.87%	34.64%	55.37%
EPS in Rs	5.95	5.01	7.55	9.58	3.59	4.48	5.98	9.36	10.25
Dividend Payout %					139%	134%	100%	100%

Compounded Sales Growth

5 Years:: 10%
3 Years:: 17%
TTM:: 23%

Compounded Profit Growth

5 Years:: 4%
3 Years:: 38%
TTM:: 53%

Stock Price CAGR

5 Years:: 5%
3 Years:: 37%
1 Year:: 14%

Return on Equity

4 Years:: 18%
Last Year:: 29%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. EPS restated for bonus issues and splits. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	53	53	53	159
Reserves	481	474	494	426
	23	42	25	51
Long term borrowings		11
Short term borrowings		11
	75	75	121	111
Trade payables	24	40	76	65
Minority interest	1	1	0	1
Current liabilities	77	90	122	110
Total Liabilities	633	644	693	747
	194	204	198	209
Gross block	359	396	440	487
Accumulated depreciation	165	192	242	278
Goodwill & intangibles	101	105	113	112
CWIP	2	3	14	3
	437	438	480	535
Inventories	28	48	47	48
Trade receivables	85	43	73	74
Cash & equivalents	18	9	18	38
Current assets	273	279	338	372
Total Assets	633	644	693	747

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	129	168	180	213
Profit for the year	64	71	92	163
Working capital changes	6	30	11	-8
Direct taxes paid	-28	-29	-51	-60
	-39	-91	-41	-23
Fixed assets purchased	-44	-62	-33	-21
Fixed assets sold	2	1	0	5
Investments purchased	-192	-28	-7	-11
Investments sold	193		8
	-86	-85	-130	-170
Proceeds from borrowings		29
Repayment of borrowings		-7	-22
Interest paid	-2	-7	-3	-3
Dividends paid	-79	-95	-95	-148
Net Cash Flow	4	-8	8	21
Free Cash Flow	86	106	146	192

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROE	—	12.1%	13.3%	17.0%	28.8%
ROCE	—	16.4%	18.1%	26.0%	33.8%
Operating margin	—	16.4%	16.3%	19.9%	24.9%
Net margin	—	12.5%	12.5%	13.4%	19.8%
Debt / equity	—	0.04	0.08	0.05	0.09
Current ratio	—	3.54	3.08	2.77	3.39
Debtor days	—	60	28	39	33
Inventory days	—	62	104	89	81
Days payable	—	54	88	146	109
Cash conversion cycle	—	68	44	-18	5
Working capital days	—	138	121	116	117

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

Promoters 51.02%
FIIs 9.37%
DIIs 25.92%
Public 13.70%

%	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	71.11%	71.11%	71.11%	71.11%	71.06%	71.06%	71.06%	71.06%	60.93%	60.92%	60.92%	51.02%
	3.35%	2.90%	2.49%	1.93%	2.77%	2.41%	3.23%	4.85%	4.95%	5.37%	5.44%	9.37%
Foreign portfolio investors (Cat. I)	3.28%	2.80%	2.36%	1.61%	2.40%	2.19%	3.05%	4.30%	4.76%	5.07%	5.03%	7.63%
Foreign portfolio investors (Cat. II)	0.07%	0.10%	0.13%	0.32%	0.37%	0.22%	0.18%	0.55%	0.20%	0.30%	0.40%	1.74%
	13.89%	14.88%	14.90%	14.80%	14.67%	14.97%	14.54%	13.47%	20.51%	20.99%	20.92%	25.92%
Mutual funds	12.47%	12.94%	12.84%	12.90%	12.75%	12.97%	12.66%	11.89%	18.60%	19.45%	19.86%	22.91%
Insurance companies	1.08%	1.08%	1.08%	1.08%	1.06%	1.06%	1.06%	0.86%	0.72%	0.37%	0.12%	1.91%
Alternative investment funds	0.34%	0.86%	0.97%	0.81%	0.87%	0.94%	0.82%	0.72%	1.20%	1.18%	0.94%	1.10%
	11.65%	11.10%	11.50%	12.16%	11.49%	11.56%	11.17%	10.63%	13.61%	12.71%	12.72%	13.70%
Retail (up to ₹2 lakh)	7.72%	7.47%	7.53%	7.58%	7.27%	7.57%	7.09%	7.42%	8.92%	8.54%	8.57%	8.97%
HNIs (above ₹2 lakh)	1.42%	1.01%	1.13%	2.20%	1.89%	1.64%	1.86%	0.77%	1.95%	1.64%	1.78%	1.95%
NRIs	1.17%	1.16%	1.13%	0.65%	0.67%	0.68%	0.62%	0.65%	0.76%	0.77%	0.77%	0.80%
Bodies corporate	0.95%	1.02%	1.24%	1.33%	1.25%	1.26%	1.18%	1.21%	1.31%	1.11%	0.95%	1.36%
No. of Shareholders	68,844	64,823	61,636	59,377	56,666	57,403	54,566	54,142	77,619	73,377	73,064	75,186

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Mutual funds & institutions holding Thyrocare Technologies

Holder (above 1%)	Stake
HSBC Aggressive Hybrid FundMutual fund	6.79%
Nippon India Pharma FundMutual fund	5.66%
ICICI Prudential Active Momentum FundMutual fund	3.72%
Aditya Birla Sun Life Business Cycle FundMutual fund	3.51%
Kotak Mahindra Life Insurance Company Ltd.Insurance	1.57%

As named in the shareholding pattern for Sep 2026 filed with NSE; mutual funds together hold 22.91% of the company. Shareholders below 1% are not named in the filing.

Documents

Announcements

All announcements on NSE →

Annual reports

Credit ratings

None filed recently.

Concalls & investor meets

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Ex-dividend date: 23 Jun 2026
Latest quarter: 30 Jun 2026
Financial year end: 31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an account How it works

Latest news

In the news

No recent coverage found.

From the company (NSE)

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.

Questions about Thyrocare Technologies Limited

What is the share price of Thyrocare Technologies Limited today?

Thyrocare Technologies Limited (THYROCARE) last traded at ₹485.25 on NSE (16 Oct 2026, 3:30 PM IST). Prices may be delayed.

What is the market cap of Thyrocare Technologies Limited?

About ₹7,723 crore at the latest price.

What is the P/E ratio of Thyrocare Technologies Limited?

About 44.0 times its earnings over the last 12 months.

Is Thyrocare Technologies Limited a good investment?

We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.

How can I buy Thyrocare Technologies Limited shares?

You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.

Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).

Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Get in touch

We typically respond within 2 hours on business days.

Call us

CA Amit Kumar Jain+91 93522 44475 Arihant Jain+91 80056 49698 Poornima Jain+91 92525 44475

Email ussupport@plenitude.co.in

WhatsAppChat with an expert

Visit us5C, Laxmi Colony, Near Bohra Ji Ka Bagh, Opp. Laxmi Mandir Cinema, Tonk Road, Jaipur, Rajasthan 302015

Mon–Sat · 10:00 AM – 7:00 PM IST

In your free consultation

A health check of your current investments
A goal-based plan for retirement, education or a home
Ways to save tax that fit your situation
Clear next steps, with zero pressure to invest

2,000+Investors

₹250 Cr+Client assets

15+ yrsExperience

AMFI Registered Mutual Fund Distributor · ARN-130934

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

100% free
No obligation
Reply within 2 hours

First name *

Last name *

Email *

Phone *

+91

I'm interested in *

Best day for a call

Preferred time

How can we help? (optional)

Upload your portfolio (optional, get a free expert review)Attach your portfolio statement · PDF, Excel or CSV (e.g. CAS), max 10 MB

I consent to being contacted by Plenitude Connect about financial services. My data will be handled as per the Privacy Policy.

Join 2,000+ investors who plan with Plenitude

Your details are private and never shared.

Thyrocare Technologies Limited share price

Price chart

Quick take

Pros

Cons

AI analysis

About Thyrocare Technologies Limited

Peer comparison

Quarterly Results

Profit & Loss

Projection — your assumptions

Related party transactions

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Mutual funds & institutions holding Thyrocare Technologies

Documents

Announcements

Annual reports

Credit ratings

Concalls & investor meets

Key dates

Trade with our broking desk

Latest news

In the news

From the company (NSE)

Questions about Thyrocare Technologies Limited

Have a question about this topic?

Book your free wealth consultation

Request received!

What happens next